Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,049 across all filing types
Latest filing 2022-04-08 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
General updates
Regulatory Filings
2022-04-08 English
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 95% confidence The document is a Regulation 31(4) annual declaration listing promoters and promoter groups of Glenmark Pharmaceuticals Limited for the financial year ending 31-Mar-2022. This type of filing is a notification of major shareholding or promoter holdings as per regulatory requirements. It does not contain financial statements or management discussion, nor is it an announcement of a report publication. It fits the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding disclosures, confirming this classification.
2022-04-08 English
General updates
Regulatory Filings Classification · 95% confidence The document text is extremely short (178 characters) and contains only references to omitted pictures and an annexure label, with no substantive content or financial data. There is no indication of any report, announcement, or detailed information. Given the lack of content, this document does not represent a full report or announcement but likely an attachment or supplementary material. According to the rules, such minimal content without actual report data or announcements defaults to Regulatory Filings (RNS).
2022-04-07 English
Re-appointment
Regulatory Filings
2022-04-07 English
Loss of share certificate
Regulatory Filings Classification · 90% confidence The document contains a table listing shareholder names, folio numbers, certificate numbers, and number of shares. It appears to be a record of share ownership or share certificates. There is no indication of financial data, management discussion, voting results, or regulatory announcements. The document is very short (320 characters) and does not contain any report or announcement text. It resembles a shareholding or share certificate record but does not fit the category of Major Shareholding Notification (MRQ) because it does not indicate threshold crossing or changes. It also does not fit other categories like Director's Dealing or Share Issue. Given the lack of fit to any specific category, the best classification is Regulatory Filings (RNS) as a fallback for miscellaneous filings that do not neatly fit elsewhere.
2022-04-01 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Glenmark Pharmaceuticals has received ANDA approval from the U.S. FDA for a specific drug product. It is addressed to stock exchanges and includes a media release for immediate distribution. There are no financial statements, detailed financial analysis, or regulatory filings such as annual or quarterly reports. The content focuses on a product approval and company update rather than financial results or governance. The document length is 4483 characters, which is relatively short and consistent with a press release. This fits best under the category of a Capital/Financing Update (CAP) since it relates to regulatory approval impacting the company's product portfolio and potential market launch, which is a material business update relevant to investors and capital markets. It is not an earnings release or annual report, nor is it a regulatory filing or announcement of voting results. Therefore, the most appropriate classification is CAP with high confidence.
2022-03-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.